Spero Therapeutics SPRO is preparing to release its quarterly earnings on Thursday, 2024-11-14. Here's a brief overview of ...
Spero Therapeutics Inc (NASDAQ:SPRO) is set to release its Q3 2024 earnings on Nov 14, 2024. The consensus estimate for Q3 ...
Pittsburgh Steelers (Ian Eagle, Charles Davis, Evan Washburn) Blue: Jacksonville Jaguars vs. Detroit Lions (Kevin Harlan, ...
Spero Therapeutics Inc. is pulling the plug on a lung disease drug trial and reducing its workforce by 39%. The Cambridge ...
Titans Wire on MSN4 小时
If you're in the yellow, you'll get Titans vs. Vikings on TVThose in the yellow region of the TV map will get the game on the local CBS channel. Getting the call for this game will be ...
GlobalData on MSN14 天
Spero’s stock slides after antibiotic flops in Phase II trialThe company has also laid off 39% of its staff as it discontinued the development of SPR720 for non-tuberculous mycobacterial ...
Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero ...
Getting a win against the Colts could be the spark this team needs. Minnesota Vikings @ Tennessee Titans – CBS – 1:00 PM ET – ...
马萨诸塞州剑桥 - Spero Therapeutics, Inc. (NASDAQ:SPRO)宣布暂停其SPR720开发项目，此前一项中期分析显示，该药物在非结核分枝杆菌肺病 (NTM-PD)治疗的2a期概念验证研究中未能达到主要终点。这项包含16名患者数据的分析显示，与安慰剂相比差异不足，并存在潜在的剂量限制性安全问题，包括可逆的3级肝毒性病例。
在充满挑战的市场环境中，Spero Therapeutics Inc. (SPRO)股票触及52周低点，跌至1.03美元。尽管整体市场波动，该公司股票在过去一年仍录得21.3%的涨幅。这种近期低点与年度增长之间的对比反映了生物制药板块的动态性质，在这个板块中，投资者情绪很容易受到监管新闻、临床试验结果和合作伙伴关系发展的影响。Spero Therapeutics以开发治疗多重耐药细菌感染的疗法而闻 ...
They pointed out that unlike Canada, the U.S. president did not announce his apology alongside any meaningful next steps beyond verbal acknowledgement. Spero Manson, medical anthropologist and ...
一些您可能无法访问的结果已被隐去。
显示无法访问的结果
反馈